|
市場調查報告書
肺動脈高血壓帶給新藥、既有藥物的機會
Pulmonary Arterial Hypertension Market Offers Opportunity for New and Established Agents
|
本報告已在2011年12月21日停止出版。
肺動脈高血壓市場由於缺乏有效的治療方法，並隨著多重用藥的情況增加，其發展備受期待，也給新產品帶來很好的進入市場的機會。
專門於醫療產業相關廣泛調查的美國市調公司 Decision Resources Inc. （總公司：麻薩諸塞州），針對肺動脈高血壓帶給新藥及既有藥物的機會進行調查分析，並系統整理調查結果後出版報告書 "Pulmonary Arterial Hypertension Market Offers Opportunity for New and Established Agents" 。
本報告書內容包括：肺動脈高血壓概要、已經認可的治療藥及未來很有希望的治療藥趨勢、至2010年為止該市場的發展預測等。內容綱要摘記如下：
實施概要
具有吸引力的治療標的
肺動脈高血壓概要
- 疾病的特徵、診斷、罹患趨勢
- 風險因素、病病的路徑、藥物標的
經認可的藥物療法
- Flolan
- Tracleer
- Revatio
- Remodulin
- Ventavis
- 其他藥物療法
- 併用療法
很有希望的新治療法
- 新的皮內素受體對抗藥：Ambrisentan 對 Thelin
- 重新調整處方之類前列環素：吸入式、口服式Remodulin
- PDE-5抗化劑：Cialis、Levitra、UK-369003
- 血管活性腸管縮氨酸衍生物：Aviptadil
- 血清素路徑對抗藥：PRX-08066及Cipralex/Lexapro
- 酪氨酸激酶抗化劑：Gleevec
- 其他產品線藥
未來發展前景
- 促進及阻礙市場發展因素
- 至2010年為止的肺動脈高血壓市場預測
表
- 肺動脈高血壓的患者人數：2005年
- 現在及未來肺動脈高血壓治療的分子標的
- 肺動脈高血壓相關已投入市場的藥物
- 針對肺動脈高血壓的新興治療
- 主要肺動脈高血壓治療藥各類銷售預測：2010年
圖
- 肺動脈高血壓的分類
- 肺動脈高血壓的風險因素
- 主要7國目前肺動脈高血壓治療的市場佔有率：2005年
Abstract
Introduction
Pulmonary arterial hypertension (PAH) is a rare but fatal disease that
severely compromises pulmonary and cardiovascular function. New treatment
guidelines and increasing awareness of PAH are rapidly expanding the treatable
patient population. Once the exclusive domain of specialty pharma and small
biotech fi rms, PAH is now attracting the attention of a wider scope of
companies looking to enter this compact but lucrative market.
Get the Answers You Need to Shape Your Strategy
Actelion's Tracleer (bosentan) was the fi rst oral drug to gain widespread
approval for PAH and is currently the dominant player in the PAH market.
However, a signifi cant need for conveniently formulated, effi cacious, and
reasonably priced alternatives remains.
Which agents-established and emerging-are poised to challenge Tracleer?
A growing treatable patient population and a shift from monotherapy to a
multimodal treatment approach are expanding the PAH market.
What other attractive qualities does the PAH market have, and what opportunities does it present for drug manufacturers?
Pfizer has expanded the reach of its lifestyle drug Viagra (sildenafi l) by
gaining approval to include PAH in its list of indications.
Which other manufacturers plan to follow the same strategy with their established therapies?
Scope
- Overview of PAH: disease characteristics, diagnosis, prevalent
cases, risk factors, disease pathways, and drug targets.
- Approved drug therapies: Flolan, Tracleer, Revatio, Remodulin,
Ventavis, Procylin, combination therapy.
- Promising new therapies: novel endothelin receptor antagonists,
reformulated prostacyclin analogues, PDE-5 inhibitors, vasoactive intestinal
peptide derivatives, serotonin pathway antagonists, tyrosine kinase
inhibitors, and others.
- Outlook: market drivers and constraints, and forecast of the PAH
market through 2010.
Mentioned in This Spectrum Report
Companies
- Actelion
- Astellas Pharma
- Bayer-Schering AG
- Biogen Idec
- Cotherix
- Eli Lilly
- Encysive
- Epix
- Forest
- Gilead Sciences
- GlaxoSmithKline
- ICOS
- Kaken Pharmaceuticals
- Lundbeck
- mondoBiotech
- Myogen
- Novartis
- Pfi zer
- PR Pharmaceuticals
- United Therapeutics
Table of Contents
- Executive Summary
- Strategic Considerations
- Stakeholder Implications
- An Attractive Target
- Overview of PAH
- Disease Characteristics, Diagnosis, and Prevalent Cases
- Risk Factors, Disease Pathways, and Drug Targets
- Approved Drug Therapies
- Flolan
- Tracleer
- Revatio
- Remodulin
- Ventavis
- Other Drug Therapies
- Combination Therapy
- Promising New Therapies
- Novel Endothelin Receptor Antagonists: Ambrisentan vs Thelin
- Reformulated Prostacyclin Analogues: Inhaled and Oral Remodulin
- PDE-5 Inhibitors: Cialis, Levitra, and UK-369003
- Vasoactive Intestinal Peptide Derivatives: Aviptadil
- Serotonin Pathway Antagonists: PRX-08066 and Cipralex/Lexapro
- Tyrosine Kinase Inhibitors: Gleevec
- Other Promising Pipeline Agents
- Outlook
- Market Drivers and Constraints
- Pulmonary Arterial Hypertension Market Through 2010
Tables
- 1. Prevalence of Pulmonary Arterial Hypertension, 2005
- 2. Molecular Targets for Current and Future PAH Therapies
- 3. Major Marketed Drugs for PAH
- 4. Emerging Therapies for the Treatment of Pulmonary Hypertension
- 5. Approval Status of Current PAH Therapies
- 6. Forecast of Regional Sales of Major PAH Drug Classes, 2010
Figures
- 1. Classifications of Pulmonary Arterial Hypertension
- 2. Risk Factors for Pulmonary Arterial Hypertension
- 3. Market Share of Current PAH Therapies in the Seven Major Markets, 2005
|
